Oncomine Dx Express Test
Life Technologies Corporation · Decision date Jul 2, 2025
What did the FDA approve?
FDA records P240040 as an original PMA application. The recorded decision is approval, dated Jul 2, 2025.
FDA approval order statement
Approval for the Oncomine Dx Express Test. The test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology to detect substitutions, insertions, and deletions in 42 genes from DNA, copy number variants (CNVs) in 10 genes from DNA, and fusions or splice variants in 18 genes from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor samples, using the Genexus Dx Integrated Sequencer. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling (see approval order for Table 1).Additionally, the test is intended to provide tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Jul 2, 2025
Regulatory record facts
- Identifier
- P240040
- Regulatory pathway
- Premarket approval application
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Jul 2, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240040 received
Application receipt date recorded by FDA.
P240040 · FDA decision
APPR
P240040/S005 · Related supplement
Oncomine Dx Express Test
P240040/S008 · Related supplement
Oncomine Dx Express Test
Timeline entries are records held by MedtechLedger for P240040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S005 | Life Technologies Corporation | PMA supplement | Sep 9, 2026 | FDA |
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Life Technologies Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7335 Executive Way, Frederick, MD, 21704
Sources and methodology
- Original FDA record: P240040
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



